cobicistat / elvitegravir / emtricitabine / tenofovir alafenamide Oral Tablet

Brand(s)
Genvoya
Category(s)
prescription
SPL Type(s)
Human Prescription
Master SPL
Gilead Sciences, Inc. (2015-11-09)
Oldest Current Product
2015-11-05
License(s)
NDA
RxNORM
ORAL TABLET\COBICISTAT:ELVITEGRAVIR:EMTRICITABINE:TENOFOVIR ALAFENAMIDE
SPL Active
ORAL\TABLET\COBICISTAT: ELVITEGRAVIR: EMTRICITABINE: TENOFOVIR ALAFENAMIDE FUMARATE
SPL Moiety
ORAL\TABLET\COBICISTAT: ELVITEGRAVIR: EMTRICITABINE: TENOFOVIR ALAFENAMIDE

product(s) by strength(s)

cobicistat 150 mg / elvitegravir 150 mg / emtricitabine 200 mg / tenofovir alafenamide 10 mg oral tablet

product(s)(s)

#idbrandcategorylabelerfirst marketedactive ingredient(s)routedose formapplicationspl
1619581901GenvoyaNDAGilead Sciences, Inc.2015-11-05COBICISTAT, ELVITEGRAVIR, EMTRICITABINE, TENOFOVIR ALAFENAMIDE FUMARATEORALTABLETNDA20756134784acf-15ed-4715-b504-eb30430518e9

spl(s)

#idtitlecategorytypelabelerlast updateversionproduct(s)
134784acf-15ed-4715-b504-eb30430518e9 (view SPL)These highlights do not include all the information needed to use GENVOYA safely and effectively. See full prescribing information for GENVOYA. GENVOYA (elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) tablets, for oral use Initial U.S. Approval: 2015prescriptionHuman PrescriptionGilead Sciences, Inc.2015-11-091619581901

Data from: LOINC, MTHSPL, NDFRT, NCIT, RxNORM, UNII